Oncolytics Biotech Inc (ONCY) stock
Close on Nov 12, 2026Market cap $47.43MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- C$66.91M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Diluted shares
- 120M
Trading
- Previous close
- $0.41
- Open
- $0.41
- Day's range
- $0.37 – $0.42
- Volume
- 818,337
- Average volume (20 days)
- 979,165
- Beta (5 years)
- 1.05
- RSI (14 days)
- 31.5
- Volatility (1 year)
- 81.7%
- Relative volume
- 0.70×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ONCY | S&P 500 | Difference | ONCY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -21.4% | -2.7% | −18.7 pts | ||
| 3 months | -54.8% | -1.7% | −53.1 pts | ||
| Year to date | -57.4% | +11.9% | −69.3 pts | ||
| 1 year | -67.2% | +12.0% | −79.2 pts | ||
| 3 years | -74.3% | +78.2% | −152.5 pts | -36.5% | +21.2% |
| 5 years | -81.1% | +73.2% | −154.4 pts | -28.4% | +11.6% |
| 10 years | -80.4% | +309.6% | −390.1 pts | -15.0% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025, CAD
Revenue
Operating income
EPS, diluted
Press releases
Releases Oncolytics Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Oncolytics Biotech
Pharmaceutical Preparations
Oncolytics Biotech is a clinical-stage biopharmaceutical enterprise focused on developing pelareorep, an intravenously administered immunotherapeutic candidate. Pelareorep is a proprietary isolate of reovirus designed to replicate selectively inside RAS-mutated tumor cells, stimulate innate and adaptive immune defenses, and transform the immunosuppressive microenvironment of solid tumors. The firm prioritizes platform development for gastrointestinal malignancies—including pancreatic ductal adenocarcinoma, anal canal carcinoma, and metastatic colorectal cancer—alongside clinical evaluations in breast cancer. These investigational programs aim to improve clinical responses when paired with chemotherapy or checkpoint inhibitors. Target beneficiaries comprise oncology patients who have exhausted or derived minimal benefit from current standard cancer therapies.
Company profile, executives and historyOncolytics Biotech stock: common questions
What is Oncolytics Biotech's stock price?
ONCY closed at $0.37 on Nov 12, 2026, down 9.62% on the day.
What is Oncolytics Biotech's market cap?
Oncolytics Biotech was worth $47.43M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
Does Oncolytics Biotech pay a dividend?
No. Oncolytics Biotech has not paid a cash dividend over the last twelve months.
How has ONCY stock performed over the past year?
Including dividends, ONCY returned -67.2% over the past year, against +12.0% for the S&P 500.
Who are Oncolytics Biotech's competitors?
Companies most similar to Oncolytics Biotech by business, industry and size include ZNTL, PLRX, TOVX, ELTX, GNLX.
See a number that looks wrong?